FDA Wants Risk Assessments To Support Post-Approval Changes For Biologicals
Executive Summary
FDA has issued draft guidance calling for a risk management approach to assigning manufacturing change categories for licensed biological products. It updates a 20-year old version.
You may also be interested in...
Global Post-Approval Changes Outlook Murky As Q12 Lurches Into Consultation
ICH finally proposes a way to resolve the regulatory complexity that has prevented drug makers from establishing and perfecting global approaches to manufacturing their drug products. But with legal concerns persisting in Europe and possibly lurking elsewhere, approval of ICH's draft Q12 guideline could be difficult.
FDA Clarifies Criteria for Accepting Reportable Manufacturing Changes For Biologics
To reduce the number of unnecessary supplements being submitted to the agency, US FDA draft guidance clarifies which types of biologics manufacturing changes are considered minor and can be included in annual reports. The agency said that too many minor changes are being submitted as supplements.
FDA Would Establish Conditions for Swift Manufacturing Changes
FDA draft 'conditions established' guidance proposes to smooth the way for continual improvement of manufacturing processes for drugs and biologics by saying which manufacturing changes don't need to be reported.